Mergers & Acquisitions ·
Medicus Pharma's Skinject agrees to proposed $135M SPAC business combination
MDCXMedicus Pharma Ltd.
Medicus Pharma Ltd.'s wholly-owned subsidiary, Skinject Inc., has entered into a non-binding letter of intent with an undisclosed special purpose acquisition company for a proposed business combination. The transaction values Skinject at approximately $135 million pre-money and includes concurrent equity financing to support the SKNJCT-005 NDA-enabling study in Gorlin Syndrome patients. Medicus intends to retain majority economic and voting ownership of the combined entity, which is expected to be separately listed. Completion is subject to due diligence, definitive agreements, shareholder approvals, and other customary closing conditions, with an anticipated close in the first half of 2027. The company also announced a conference call for November 9, 2026, to discuss financial performance and strategic updates including a potential CD228V co-development agreement with Pfizer. Medicus Pharma Ltd. is a precision-guided biotech/life sciences company focused on advancing clinical development programs of novel therapeutic assets.